FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing
![](https://www.mcalindenresearchpartners.com/wp-content/uploads/2022/12/blood-g9c3e756ad_1920-1024x683.jpg)
Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022